Armata Pharmaceuticals Reports Positive Phase 2a Results for AP-SA02 in Staph Aureus Bacteremia
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company specializing in bacteriophage therapeutics, announced that it will be featured in a key opinion leader webinar on November 25, 2025, focusing on Staphylococcus aureus (S. aureus) bacteremia and its investigational phage therapy, AP-SA02. The company previously presented positive results from its diSArm study at IDWeek 2025. The diSArm study was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability, and efficacy of intravenous AP-SA02 in combination with best available antibiotic therapy (BAT) versus BAT alone in adults with complicated S. aureus bacteremia. Results indicated that the combination of AP-SA02 and BAT achieved higher and earlier cure rates compared to BAT alone, with AP-SA02 showing a 100% response rate without relapse at key follow-up points, while the placebo group exhibited an approximate 25% relapse or lack of response. AP-SA02 was reported to be well-tolerated and demonstrated efficacy against both methicillin-resistant and methicillin-sensitive S. aureus.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA26423) on November 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.